Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer

por Kosmas, C, Mylonakis, N, Tsakonas, G, Vorgias, G, Karvounis, N, Tsavaris, N, Daladimos, T, Kalinoglou, N, Malamos, N, Akrivos, T, Karabelis, A
Publicado 2009

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

por White, N M A, Mathews, M, Yousef, G M, Prizada, A, Popadiuk, C, Doré, J J E
Publicado 2009

S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility

por Nedjadi, T, Kitteringham, N, Campbell, F, Jenkins, R E, Park, B K, Navarro, P, Ashcroft, F, Tepikin, A, Neoptolemos, J P, Costello, E
Publicado 2009

Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis

por Cunningham, J M, Vierkant, R A, Sellers, T A, Phelan, C, Rider, D N, Liebow, M, Schildkraut, J, Berchuck, A, Couch, F J, Wang, X, Fridley, B L, Gentry-Maharaj, A, Menon, U, Hogdall, E, Kjaer, S, Whittemore, A, DiCioccio, R, Song, H, Gayther, S A, Ramus, S J, Pharaoh, P D P, Goode, E L
Publicado 2009

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)

por Pinto, C, Di Fabio, F, Barone, C, Siena, S, Falcone, A, Cascinu, S, Rojas Llimpe, F L, Stella, G, Schinzari, G, Artale, S, Mutri, V, Giaquinta, S, Giannetta, L, Bardelli, A, Martoni, A A
Publicado 2009

Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme

por van Rossum, L G M, van Rijn, A F, Laheij, R J F, van Oijen, M G H, Fockens, P, Jansen, J B M J, Verbeek, A L M, Dekker, E
Publicado 2009

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

por Mellado, B, Font, A, Alcaraz, A, Aparicio, L A, Veiga, F J G, Areal, J, Gallardo, E, Hannaoui, N, Lorenzo, J R M, Sousa, A, Fernandez, P L, Gascon, P
Publicado 2009

Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes

por Stumpf, M, Hasenburg, A, Riener, M-O, Jütting, U, Wang, C, Shen, Y, Orlowska-Volk, M, Fisch, P, Wang, Z, Gitsch, G, Werner, M, Lassmann, S
Publicado 2009

Impaired TNFα-induced A20 expression in E1A/Ras-transformed cells

por Huang, H-L, Yeh, W-C, Lai, M-Z, Mirtsos, C, Chau, H, Chou, C-H, Benchimol, S
Publicado 2009

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

por Novello, S, Scagliotti, G V, Rosell, R, Socinski, M A, Brahmer, J, Atkins, J, Pallares, C, Burgess, R, Tye, L, Selaru, P, Wang, E, Chao, R, Govindan, R
Publicado 2009

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

por Konecny, G E, Glas, R, Dering, J, Manivong, K, Qi, J, Finn, R S, Yang, G R, Hong, K-L, Ginther, C, Winterhoff, B, Gao, G, Brugge, J, Slamon, D J
Publicado 2009

Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis

por Ashraf, S Q, Umana, P, Mössner, E, Ntouroupi, T, Brünker, P, Schmidt, C, Wilding, J L, Mortensen, N J, Bodmer, W F
Publicado 2009

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

por Toi, M, Iwata, H, Fujiwara, Y, Ito, Y, Nakamura, S, Tokuda, Y, Taguchi, T, Rai, Y, Aogi, K, Arai, T, Watanabe, J, Wakamatsu, T, Katsura, K, Ellis, C E, Gagnon, R C, Allen, K E, Sasaki, Y, Takashima, S
Publicado 2009

Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer

por Jubb, A M, Turley, H, Moeller, H C, Steers, G, Han, C, Li, J-L, Leek, R, Tan, E Y, Singh, B, Mortensen, N J, Noguera-Troise, I, Pezzella, F, Gatter, K C, Thurston, G, Fox, S B, Harris, A L
Publicado 2009

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients

por Jernström, H, Bågeman, E, Rose, C, Jönsson, P-E, Ingvar, C
Publicado 2009

Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil i...

por Wilkowski, R, Boeck, S, Ostermaier, S, Sauer, R, Herbst, M, Fietkau, R, Flentje, M, Miethe, S, Boettcher, H D, Scholten, T, Bruns, C J, Rau, H G, Hinke, A, Heinemann, V
Publicado 2009

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

por Reardon, D A, Desjardins, A, Vredenburgh, J J, Gururangan, S, Sampson, J H, Sathornsumetee, S, McLendon, R E, Herndon, J E, Marcello, J E, Norfleet, J, Friedman, A H, Bigner, D D, Friedman, H S
Publicado 2009

Epoetin-β treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromb...

por Aapro, M, Osterwalder, B, Scherhag, A, Burger, H U
Publicado 2009

Second solid cancers after radiotherapy for breast cancer in SEER cancer registries

por Berrington de Gonzalez, A, Curtis, R E, Gilbert, E, Berg, C D, Smith, S A, Stovall, M, Ron, E
Publicado 2010

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

por Conroy, T, Hebbar, M, Bennouna, J, Ducreux, M, Ychou, M, Llédo, G, Adenis, A, Faroux, R, Rebischung, C, Kockler, L, Douillard, J Y
Publicado 2010